Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Key Points

• Oculis Holding AG experienced a substantial decline in short interest, falling 71.1% to 11,700 shares by August 31st, with a short-interest ratio of 0.7 days based on average trading volume.
• Institutional investors, including Bank of America and Citadel Advisors, have increased their stakes in Oculis, with 22.30% of the stock currently owned by such investors.
• Despite recently receiving analyst upgrades and maintaining a "buy" rating among four brokerages, Oculis reported a quarterly EPS loss of ($0.59), missing consensus estimates by ($0.06).

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 11,700 shares, a decline of 71.1% from the August 15th total of 40,500 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 16,200 shares, the short-interest ratio is presently 0.7 days. Based on an average trading volume of 16,200 shares, the short-interest ratio is presently 0.7 days. Approximately 0.0% of the shares of the stock are short sold.

Hedge Funds Weigh In On Oculis

Several institutional investors and hedge funds have recently modified their holdings of OCS. Kestra Private Wealth Services LLC acquired a new position in shares of Oculis in the first quarter valued at $234,000. Bosun Asset Management LLC acquired a new stake in shares of Oculis in the second quarter valued at about $378,000. Citadel Advisors LLC acquired a new position in shares of Oculis in the fourth quarter worth approximately $389,000. Marshall Wace LLP bought a new position in shares of Oculis during the 2nd quarter worth approximately $393,000. Finally, Bank of America Corp DE raised its position in shares of Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after purchasing an additional 10,667 shares during the period. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on OCS. HC Wainwright lifted their price target on shares of Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Friday, August 22nd. Needham & Company LLC began coverage on shares of Oculis in a report on Wednesday, August 27th. They set a "buy" rating and a $36.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Oculis has an average rating of "Buy" and an average price target of $35.75.

Oculis Stock Down 0.1%

Shares of OCS stock opened at $17.22 on Friday. The stock has a market cap of $751.86 million, a P/E ratio of -6.45 and a beta of 0.26. Oculis has a one year low of $11.78 and a one year high of $23.08. The stock has a fifty day moving average price of $17.70 and a 200 day moving average price of $18.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.55 and a quick ratio of 4.55.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.14 million. Analysts predict that Oculis will post -2.09 earnings per share for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.